内源性线粒体甲酰化肽驱动FPR1信号在急性呼吸窘迫综合征中的新作用
该研究旨在明确线粒体甲酰化肽在ARDS中的存在及其通过甲酰肽受体1(FPR1)信号在无菌性肺炎症中的功能重要性。方法包括在ARDS患者BALF和血清中鉴定线粒体甲酰化肽,体外评估对人中性粒细胞的作用,以及小鼠肺损伤模型和骨髓嵌合体实验。结果显示线粒体甲酰化肽在ARDS患者BALF和血清中升高,通过FPR1依赖机制驱动中性粒细胞活化和趋化,Fpr1-/-小鼠炎症减轻,FPR1拮抗剂即使在损伤发生后给药也能减轻炎症,且髓系和实质细胞FPR1均参与肺炎症。结论首次明确线粒体甲酰化肽在人类疾病中的存在,揭示FPR1信号是无菌性急性肺损伤的关键驱动因素和ARDS的潜在治疗靶点。
要点
- ARDS患者BALF和血清中线粒体甲酰化肽升高
- 线粒体甲酰化肽通过FPR1依赖机制驱动中性粒细胞活化和趋化
- FPR1拮抗剂在损伤发生后给药仍可减轻小鼠肺炎症
核心结论
- 线粒体甲酰化肽在ARDS患者中升高,并通过FPR1信号驱动无菌性急性肺损伤,是ARDS的潜在治疗靶点。
研究设计与样本
- 研究采用液相色谱-串联质谱鉴定ARDS患者BALF和血清中的线粒体甲酰化肽;体外用线粒体甲酰化肽刺激人中性粒细胞,通过流式细胞术和趋化实验评估效果;小鼠肺损伤由线粒体甲酰化肽或盐酸诱导;骨髓嵌合体确定髓系和实质FPR1的贡献。
主要发现
- 线粒体甲酰化肽在ARDS患者BALF和血清中升高。
- 线粒体甲酰化肽通过FPR1依赖机制在体外和体内驱动中性粒细胞活化和趋化。
- 小鼠肺损伤中,Fpr1-/-小鼠炎症减轻,FPR1拮抗剂即使在损伤发生后给药也能重现该效果。
- FPR1表达存在于肺泡上皮,嵌合小鼠显示髓系和实质FPR1均参与肺炎症。
临床怎么用
- FPR1信号通路可能作为ARDS的治疗靶点,FPR1拮抗剂在损伤发生后给药仍有效,提示治疗时间窗可能较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute respiratory distress syndrome (ARDS) is an often fatal neutrophil-dominant lung disease. Although influenced by multiple proinflammatory mediators, identification of suitable therapeutic candidates remains elusive. We aimed to delineate the presence of mitochondrial formylated peptides in ARDS and characterise the functional importance of formyl peptide receptor 1 (FPR1) signalling in sterile lung inflammation. METHODS: Mitochondrial formylated peptides were identified in bronchoalveolar lavage fluid (BALF) and serum of patients with ARDS by liquid chromatography-tandem mass spectrometry. In vitro, human neutrophils were stimulated with mitochondrial formylated peptides and their effects assessed by flow cytometry and chemotaxis assay. Mouse lung injury was induced by mitochondrial formylated peptides or hydrochloric acid. Bone marrow chimeras determined the contribution of myeloid and parenchymal FPR1 to sterile lung inflammation. RESULTS: Mitochondrial formylated peptides were elevated in BALF and serum from patients with ARDS. These peptides drove neutrophil activation and chemotaxis through FPR1-dependent mechanisms in vitro and in vivo. In mouse lung injury, inflammation was attenuated in Fpr1-/- mice, effects recapitulated by a pharmacological FPR1 antagonist even when administered after the onset of injury. FPR1 expression was present in alveolar epithelium and chimeric mice demonstrated that both myeloid and parenchymal FPR1 contributed to lung inflammation. CONCLUSIONS: We provide the first definitive evidence of mitochondrial formylated peptides in human disease and demonstrate them to be elevated in ARDS and important in a mouse model of lung injury. This work reveals mitochondrial formylated peptide FPR1 signalling as a key driver of sterile acute lung injury and a potential therapeutic target in ARDS.
引用
- Dorward DA, Lucas CD, Doherty MK, et al. Novel role for endogenous mitochondrial formylated peptide-driven formyl peptide receptor 1 signalling in acute respiratory distress syndrome. Thorax. 2017. PMID: 28469031. doi:10.1136/thoraxjnl-2017-210030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。